Millennium Pharmacon International Total Liabilities
Millennium Pharmacon International total liabilities. Based on the latest financial reports, Millennium Pharmacon International (SDPC) has total liabilities worth Rp1.60 Trillion IDR (≈ $93.95 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Millennium Pharmacon International asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Millennium Pharmacon International (2000–2024)
Total liabilities of Millennium Pharmacon International from 2000 to 2024. This chart illustrates how Millennium Pharmacon International's total liabilities have evolved over time, based on quarterly financial data. Explore Millennium Pharmacon International strategic investment ratio to see how much of total assets are deployed in long-term investments.
Millennium Pharmacon International Competitors by Total Liabilities
The table below lists competitors of Millennium Pharmacon International ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CEKD Bhd
KLSE:0238
|
Malaysia | RM17.27 Million |
|
Shanghai Supezet Engineering Technology Corp Ltd
SHG:688121
|
China | CN¥5.71 Billion |
|
OYAK Yatirim Ortakligi AS
IS:OYAYO
|
Turkey | TL2.89 Million |
|
Energys Group Limited Ordinary Shares
NASDAQ:ENGS
|
USA | $10.36 Million |
|
Vision Sigma
TA:VISN
|
Israel | ILA284.59 Million |
|
Triton Holding Public Company Limited
BK:TRITN
|
Thailand | ฿1.53 Billion |
|
Donegal Investment Group PLC
IR:DQ7A
|
Ireland | €14.60 Million |
|
Magnum Mining and Exploration Ltd
AU:MGU
|
Australia | AU$1.11 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Millennium Pharmacon International's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SDPC current and non-current assets.
Liquidity & Leverage Metrics
Millennium Pharmacon International Total Liabilities Ratios Explained
Millennium Pharmacon International total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Millennium Pharmacon International's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Millennium Pharmacon International (2000–2024)
The table below shows the annual total liabilities of Millennium Pharmacon International from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Rp1.49 Trillion ≈ $87.27 Million |
+9.35% |
| 2023-12-31 | Rp1.36 Trillion ≈ $79.81 Million |
+19.20% |
| 2022-12-31 | Rp1.14 Trillion ≈ $66.95 Million |
+17.87% |
| 2021-12-31 | Rp969.41 Billion ≈ $56.80 Million |
+3.61% |
| 2020-12-31 | Rp935.63 Billion ≈ $54.82 Million |
-6.01% |
| 2019-12-31 | Rp995.41 Billion ≈ $58.33 Million |
+3.60% |
| 2018-12-31 | Rp960.78 Billion ≈ $56.30 Million |
+32.45% |
| 2017-12-31 | Rp725.39 Billion ≈ $42.51 Million |
+22.91% |
| 2016-12-31 | Rp590.17 Billion ≈ $34.58 Million |
+18.29% |
| 2015-12-31 | Rp498.90 Billion ≈ $29.23 Million |
+22.22% |
| 2014-12-31 | Rp408.20 Billion ≈ $23.92 Million |
+14.40% |
| 2013-12-31 | Rp356.81 Billion ≈ $20.91 Million |
+26.98% |
| 2012-12-31 | Rp280.98 Billion ≈ $16.46 Million |
+22.87% |
| 2011-12-31 | Rp228.69 Billion ≈ $13.40 Million |
+23.12% |
| 2010-12-31 | Rp185.74 Billion ≈ $10.88 Million |
+3.91% |
| 2009-12-31 | Rp178.75 Billion ≈ $10.47 Million |
-21.91% |
| 2008-12-31 | Rp228.90 Billion ≈ $13.41 Million |
+41.40% |
| 2007-12-31 | Rp161.88 Billion ≈ $9.49 Million |
+40.90% |
| 2006-12-31 | Rp114.89 Billion ≈ $6.73 Million |
+5.19% |
| 2005-12-31 | Rp109.22 Billion ≈ $6.40 Million |
+19.22% |
| 2004-12-31 | Rp91.61 Billion ≈ $5.37 Million |
+22.00% |
| 2003-12-31 | Rp75.09 Billion ≈ $4.40 Million |
+4.85% |
| 2002-12-31 | Rp71.62 Billion ≈ $4.20 Million |
+9.50% |
| 2001-12-31 | Rp65.41 Billion ≈ $3.83 Million |
-21.11% |
| 2000-12-31 | Rp82.90 Billion ≈ $4.86 Million |
-- |
About Millennium Pharmacon International
PT Millennium Pharmacon International Tbk engages in the distribution of prescription and non-prescription medicines and medical devices in Indonesia. The company was formerly known as PT NVPD Soedarpo Corporation Tbk and changed its name to PT Millennium Pharmacon International Tbk in February 1990. The company was founded in 1952 and is headquartered in Jakarta Selatan, Indonesia. PT Millennium… Read more